secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2026-09-29T10:30:19+00:00
Accession:  0001214659-26-012132
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Alzamend Neuro presents Phase 1/2A AL001 lithium brain-imaging data at ISMRT on Sept. 29, 2026
--------------------------------------------------------------------------------

- Dr. Ovidiu C. Andronesi presented Phase 1/2A results at the ISMRT Workshop on Sept. 29, 2026, covering 30 participants: 6 each healthy, bipolar, major depression, Alzheimer's, and PTSD.
- AL001 is a lithium salicylate/L-proline co-crystal; trial NCT06921590 used 7T Terra.X MRI and compared AL001 with Li2CO3 in a randomized crossover.
- Brain Li concentration trended higher after AL001 (geometric mean 4020.64 ng/g, 64% CV) vs Li2CO3 (3476.94 ng/g, 57% CV), but differences were not statistically significant.
- Non-compartmental PK AUC trended higher for AL001 (geometric mean 62230 h*ng/g, 26% CV) vs Li2CO3 (59715 h*ng/g, 25% CV); two-compartment modeling showed higher white-matter K1.
- 92% of lithium images were scored excellent to adequate, with Gwet's agreement coefficient 0.73 (95% CI 0.66-0.80).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926012132/0001214659-26-012132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926012132/x9282618k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-26-012132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer